Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04203160
Title Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Michigan Rogel Cancer Center

biliary tract cancer

intrahepatic cholangiocarcinoma

extrahepatic bile duct carcinoma

distal biliary tract carcinoma

gallbladder carcinoma


Cisplatin + Gemcitabine

Cisplatin + CPI-613 + Gemcitabine

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Arizona Cancer Center Recruiting Tucson Arizona 85724 United States Details
Northwestern University -- Lurie Comprehensive Cancer Center Not yet recruiting Chicago Illinois 60611 United States Details
University of Michigan Rogel Cancer Center Recruiting Ann Arbor Michigan 48109 United States Details
Atlantic Health System Recruiting Morristown New Jersey 07960 United States Details
University Hospitals - Seidman Cancer Center Recruiting Cleveland Ohio 44106 United States Details
Allegheny Health Network Recruiting Pittsburgh Pennsylvania 15224 United States Details
Vanderbilt-Ingram Cancer Center Recruiting Nashville Tennessee 37232 United States Details
University of Texas Southwestern -- Simmons Comprehensive Cancer Center Recruiting Dallas Texas 75390 United States Details
Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle Washington 98109 United States Details
University of Wisconsin - Carbone Cancer Center Recruiting Madison Wisconsin 53705 United States Details
*Shaded cells indicate that there was no data available from for the field